These 10 Stocks Just Rocked The Market

Page 9 of 9

1. Summit Therapeutics Inc. (NASDAQ:SMMT)

Summit Therapeutics fell by 29.5 percent week-on-week as investors had hoped for more encouraging results from the first trial of its Phase 3 study of Ivonescimab.

Summit Therapeutics Inc. (NASDAQ:SMMT) released initial results of the study last week. While it was not at all bad news, investors appeared to have been discouraged by the lack of concrete results, specifically on survival rates.

In a statement, Summit Therapeutics Inc. (NASDAQ:SMMT) said that the trial met the progression-free survival primary endpoint and showed a positive trend in the overall survival. It logged a hazard ratio of only 0.52.

On the other hand, Ivonescimab, in combination with chemotherapy, showed a positive trend in the overall survival but did not achieve a statistically significant benefit. Summit Therapeutics Inc. (NASDAQ:SMMT) said it had a hazard ratio of 0.79.

In the first quarter, Summit Therapeutics Inc. (NASDAQ:SMMT) widened its net loss by 44.6 percent to $62.9 million from $43.5 million in the same period last year, as operating expenses picked up by 57.5 percent to $66.8 million from $42.4 million year-on-year.

While we acknowledge the potential of SMMT, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SMMT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9